Dr. Nishi Suryavanshi Receives Award from ACTG Network

Date: 01/07/2022

Congratulations, Nishi Suryavanshi, recipient of ACTG’s Tuberculosis Transformative Science Group Special Contributions Award.

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...